Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of “Moderate Buy” by Analysts

Zura Bio Limited (NASDAQ:ZURA) has been assigned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $10.75.

ZURA has been the topic of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a research report on Wednesday, April 8th. Chardan Capital raised their price target on Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, March 23rd. Oppenheimer dropped their price objective on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a research note on Friday, March 20th. Finally, Wedbush reiterated an “outperform” rating and set a $15.00 price objective on shares of Zura Bio in a research report on Wednesday.

Institutional Trading of Zura Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Allworth Financial LP bought a new stake in Zura Bio during the 4th quarter valued at $30,000. Squarepoint Ops LLC raised its position in shares of Zura Bio by 34.6% in the 4th quarter. Squarepoint Ops LLC now owns 33,801 shares of the company’s stock worth $177,000 after acquiring an additional 8,680 shares in the last quarter. Bank of America Corp DE raised its position in shares of Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after acquiring an additional 9,966 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Zura Bio by 3.4% during the 1st quarter. Renaissance Technologies LLC now owns 313,300 shares of the company’s stock worth $1,864,000 after purchasing an additional 10,200 shares during the last quarter. Finally, Scientech Research LLC purchased a new stake in shares of Zura Bio during the 3rd quarter worth $45,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Trading Up 3.2%

Shares of NASDAQ:ZURA opened at $5.17 on Friday. The company has a market cap of $490.53 million, a price-to-earnings ratio of -4.74 and a beta of -0.03. Zura Bio has a 12 month low of $1.08 and a 12 month high of $7.44. The company has a 50-day moving average price of $4.46 and a 200 day moving average price of $5.30.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.05). As a group, equities analysts forecast that Zura Bio will post -0.76 EPS for the current year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.